This site is intended for Great Britain healthcare professionals only
Menu
Close
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Cibinqo 200 mg and 100 mg is a once-daily oral treatment
The dose may be decreased or increased based on tolerability and efficacy.
Cibinqo can be used with or without medicated topical therapies for atopic dermatitis
Cibinqo can be taken with or without food at approximately the same time each day
Tablets should be swallowed whole with water and should not be split, crushed or chewed
![]() |
Cibinqo 200 mg and 100 mg is a once-daily oral treatment
|
![]() |
The dose may be decreased or increased based on tolerability and efficacy.
|
![]() |
Cibinqo can be used with or without medicated topical therapies for atopic dermatitis
|
![]() |
Cibinqo can be taken with or without food at approximately the same time each day
|
Mild (eGFR 60 to <90 mL/min) | Moderate (eGFR 30 to <60 mL/min) | Severe (eGFR <30 mL/min) |
---|---|---|
No dose adjustment required | The recommended dose of Cibinqo should be reduced by half to 100 mg or 50 mg once daily | 50 mg once daily is the recommended starting dose. The maximum daily dose is 100 mg |
Cibinqo has not been studied in patients with end-stage renal disease (ESRD) on renal replacement therapy.
Mild | Moderate | Severe |
---|---|---|
No dose adjustment required | No dose adjustment required | Not studied, must not be used |
The recommended starting dose for patients ≥65 years of age is 100 mg once daily.
The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily. The safety and efficacy of Cibinqo in children under 12 years of age have not yet been established. No data are available.
Women of reproductive potential should be advised to use effective contraception during treatment and for 1 month following the final dose of Cibinqo. Pregnancy planning and prevention for females of reproductive potential should be encouraged.
Interaction | Examples | Clinical impact | Action |
---|---|---|---|
Strong CYP2C19 inhibitors | fluvoxamine, fluconazole, fluoxetine and ticlopidine | Increased exposure to Cibinqo moiety | Reduce dose of Cibinqo by half to 100 mg or 50 mg once daily |
Strong CYP2C19 or CYP2C9 inducers | rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin | Decreased exposure to Cibinqo active moiety and may result in loss of or reduced clinical response | Concomitant use of Cibinqo is not recommended |
MOA inhibitors | selegiline, isocarboxazid | Not studied in humans. Clinical impact not known | Caution should be exercised for concomitant use |
Learn more about monitoring patients on Cibinqo.
Access resources to help you support your patients on Cibinqo.
CYP=cytochrome P; eGFR=estimated glomerular filtration rate; MOA=monoamine oxidase; P-gp=P glycoprotein.
References:
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2021 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
Add indication message here. It can link a link,
and you can EMBOLDEN text
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021